Hematology & Oncology in Sierra Vista, AZ
3 verified hematology & oncology doctors in Sierra Vista.
Hematologist-oncologists treat blood disorders and cancers, coordinating chemotherapy and blood-related care.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Stephen Mayer, MD
Hematology & Oncology
CMS Open Payments· $10,645 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$10,645
Total received
4
Transactions
3
Paying companies
Top paying companies
Among the 11,711 hematology & oncology doctors we've analyzed, about 62% received any industry payment (median $1,465 among those who did). This doctor's total ranks around the 81th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US hematology & oncology doctors.
Payments to Stephen Mayer do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Sriman Swarup, MD
Hematology & Oncology
CMS Open Payments· $332.85 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$332.85
Total received
12
Transactions
12
Paying companies
Top paying companies
Among the 11,711 hematology & oncology doctors we've analyzed, about 62% received any industry payment (median $1,465 among those who did). This doctor's total ranks around the 58th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US hematology & oncology doctors.
Payments to Sriman Swarup do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Hamza Sheikh, MD
Hematology & Oncology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.